Combined treatment with apatinib for relapsed and refractory breast cancer: A report of 2 cases and related literature review
10.3781/j.issn.1000-7431.2017.44.047
- Author:
Yueming ZHANG
1
Author Information
1. Xuzhou Medical University
- Publication Type:Journal Article
- Keywords:
Apatinib;
Breast neoplasms;
Relapsed and refractory breast cancer;
Treatment outcome
- From:
Tumor
2017;37(5):518-523
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the efficacy and safety of apatinib combined with chemotherapy or endocrine therapy in the treatment of relapsed and refractory breast cancer. Methods: The clinical records of two patients with relapsed and refractory breast cancer treated with apatinib combined with chemotherapy or endocrine therapy were analyzed, and the related literatures were reviewed. Results: Two patients with relapsed and refractory breast cancer were treated with apatinib combined with chemotherapy or endocrine therapy and followed up for 10 months. The treatment outcome was stable disease. Major adverse reaction was hypertension, and the use of antihypertensive drugs could control the blood pressure in a normal range. Conclusion: Apatinib combined with chemotherapy or endocrine therapy in the treatment of relapsed and refractory breast cancer is effective, and the adverse effects are tolerated. Large-scale studies should be implemented to further determine the efficacy of this treatment protocol.
